Ellen Zane - PAREXEL International CEO

  CEO
Ms. Ellen M. Zane is an Independent Director of Parexel International Corporationrationration. She is Chairman of the Compensation Committee and a member of the Human Resources Committee. Since September 2011, Ms. Zane has served as CEO Emeritus and Vice Chair, Board of Trustees of Tufts Medical Center, an academic medical center that is the principal teaching hospital for Tufts University School of Medicine in Boston, Massachusetts. From January 2004 to September 2011, she served as President and Chief Executive Officer of Tufts Medical Center. From May 1994 to January 2004, she served as Network President for Partners Healthcare System, a physician and hospital network founded by the Harvard affiliated Massachusetts General Hospital and Brigham and Womens Hospital. Prior to 2004, Ms. Zane served as Chief Executive Officer of Quincy Hospital in Quincy, Massachusetts. Ms. Zane currently serves on the boards of directors of Boston Scientific Corporationrationration, Brooks Automation, Inc., Press Ganey Holdings, Inc., Century Capital Management Inc., and Fiduciary Trust Company.
Age: 64  CEO Since 2006      
781 487-9900  http://www.parexel.com
Zane currently serves on the boards of directors of Brooks Automation, Inc., Haemonetics Corporationrationrationration, Press Ganey Holdings, Inc., Century Capital Management Inc., and Fiduciary Trust Company. We believe Ms. Zane?s experience of over 30 years in management of large academic medical centers/hospitals and community health care related enterprises, including 21 years as an executive, is valuable to our Board and the Company.

Ellen Zane Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 0.05 % which means that it generated profit of $0.05 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.15 % meaning that it created $0.15 on every $100 dollars invested by stockholders.
The company currently holds 671.5 M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Found 7 records

CEO Since

Leonard SchleiferRegeneron Pharmaceuticals
1994
Uwe RohrhoffPerrigo Company Plc
2018
M RamanaDr Reddys Laboratories Ltd
2018
William NieburOrigin Agritech Limited
2016
Juan AlaixZoetis
2012
MARC KIKUCHIDr Reddys Laboratories Ltd
2019
Murray KesslerPerrigo Company Plc
2018

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Current Sentiment - PRXL

PAREXEL International Investor Sentiment

Most of Macroaxis users are at this time bullish on PAREXEL International Corp. What is your perspective on investing in PAREXEL International Corp? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

AUY   
Purchased few shares of
a day ago
Traded for 3.5
CDE   
Purchased one share of
a day ago
Traded for 6.61
AXU   
Purchased over 40 shares of
a day ago
Traded for 1.7
AU   
Purchased less than 1 share of
a day ago
Traded for 19.84
GFI   
Purchased one share of
a day ago
Traded for 5.46
See also Your Equity Center. Please also try Pattern Recognition module to use different pattern recognition models to time the market across multiple global exchanges.
Search macroaxis.com